Aidoc closed a $150 million Series E led by Growth Equity at Goldman Sachs Alternatives, with participation from General Catalyst, SoftBank Investment Advisors, and NVentures (NVIDIA’s venture capital arm), according to a company announcement. Total funding now exceeds $500 million, less than a year after a growth round led by General Catalyst and Square Peg.
Scale and Clearance
Aidoc’s CARE foundation model is deployed across nearly 2,000 hospitals and has analyzed more than 110 million patient cases. The company processes approximately 60 million patient cases annually. Earlier this year, CARE received what Aidoc described as a landmark first FDA clearance for a comprehensive foundation model-based triage system in clinical imaging, covering multiple conditions from a single architecture rather than requiring separate models per use case.
“By 2030, every complex diagnostic decision should be supported by AI that enables earlier detection and reduces preventable error,” said Elad Walach, Aidoc’s co-founder and CEO, in the announcement. The company plans to expand coverage across CT and X-ray, including pixel-to-draft-report capabilities, within two years.
The Vertical AI Funding Pattern
The round underscores a broader pattern in 2026 AI funding: institutional capital is flowing faster into purpose-built vertical platforms than into horizontal copilot tools. Aidoc’s pitch is regulatory moat. Its aiOS enterprise platform provides centralized governance for deploying and managing multiple FDA-cleared AI solutions, an operational layer that general-purpose AI tools cannot replicate without years of compliance engineering.
Christian Resch, Partner at Growth Equity at Goldman Sachs Alternatives, noted that Aidoc “pairs advanced technology with regulatory rigor in a way that few companies have achieved,” citing measurable results across radiology efficiency, shorter hospital stays, and financial returns, per the announcement.
What the Capital Funds
New funding will support further development of the CARE foundation model, expansion into additional clinical indications, and automated imaging draft report creation. The company also plans to drive broader global deployment of its aiOS platform as hospitals consolidate standalone AI tools under centralized operating frameworks. Diagnostic errors and delays contribute to at least 400,000 deaths annually in the United States, according to research cited in the announcement, framing the company’s expansion as both a commercial and clinical imperative.